- Lupin partners with Sandoz for biosimilar ranibizumab commercialization.
- Sandoz handles commercialization in multiple regions, excluding Germany.
- Lupin will manufacture the product and manage regulatory submissions.
- Sandoz gains exclusive rights for commercialization in Canada.
Lupin has entered into a partnership with Sandoz Group AG to commercialize its biosimilar ranibizumab, a treatment for various eye conditions. Under this agreement, Sandoz will manage commercialization efforts in several regions, including the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin is responsible for manufacturing the biosimilar and overseeing regulatory submissions in these markets. Additionally, Sandoz has secured exclusive rights to commercialize the product in Canada. The collaboration aims to enhance patient access to this biosimilar, which is expected to compete with existing therapies in the ophthalmology market. The specific financial terms of the partnership remain undisclosed, but both companies anticipate significant market opportunities given the growing demand for biosimilars globally. The agreement reflects a strategic move by both companies to leverage their strengths in manufacturing and commercialization to address unmet medical needs in various regions.
Insights
This partnership enhances patient access to affordable biosimilar treatments across multiple regions.